E-Articles - Health and Fitness

The FDA may expand warning labels for antidepressants because of fear increases in suicidal though

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ts. The proposed changes were made public yesterday( December 12th) by the U.S. Food and Drug Admi

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

nistration.

The changes would expand a warning now on the labels that applies only to children an

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

d adolescents treated with the drugs. The proposed changes would expand the labeling to include ch

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ildren, adolescents and adults 24 years and younger.

A special panel is meeting this week to cons

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ider these changes. The special panel would make a recommendation to the FDA and then the FDA woul

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

d issue its final and binding decision early next year. The panel consists of experts in psychiat

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

y, pharmacology and neuropharmacology.

Also included in the FDA proposes changes is a recommenda

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

tion that patients of all ages be carefully monitored, especially when beginning antidepressant tr

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

eatment.

Patients who are depressed and are put on antidepressants should be monitored regardless

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

of FDA recommendations. If you believe that a loved one is at risk of suicidal behavior or though

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ts, that patient should be monitored 24 hours a day.

Mental health experts are worried that addit

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ional warnings about the risk of suicides linked to antidepressants could curtail their use and ul

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

timately do more harm than good. The FDA may indeed be unnecessarily scaring patients with these w

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

rnings that are called "black-box" labels. Patients who are suffering from mental illness tend to

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

be fragile and are sensitive to alarming warnings.

The American Psychiatric Association( APA) do

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

es not endorse this type of warning. The APA's concern is that by not simply promoting good standa

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

rds of care and by putting on a black-box label, the FDA may unwittingly limit further access to c

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

are.

Vagus nerve stimulation therapy, which is the only FDA approved long term treatment option f

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

or depression, is not associated with increases suicidality in patients who have had the treatment

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-article.org.ua/article/239243/e-article-The-FDA-May-Expand-Warning-Labels-for-Antidepressants.html">The FDA May Expand Warning Labels for Antidepressants</a>

BB link (for phorums):
[url=http://www.e-article.org.ua/article/239243/e-article-The-FDA-May-Expand-Warning-Labels-for-Antidepressants.html]The FDA May Expand Warning Labels for Antidepressants[/url]

Today, printing is a significant line item on every business budget. Learn the tricks to stretch your markeitng dollars.

Flying high above it all, many entrepreneurs are looking for the capital they need to chase down their dreams. Indeed they are so in love with their concept that they think everyone should love it too. Loving your concept and having passion for it is indeed a good trait, however often the entrepreneur will go and hire someone else to find the capital for them.

We think that once our well developed and designed website is launched, magically, a large number of people will visit immediately. With the millions of websites launched weekly and monthly, we have to do some extra work to make sure that those people we want to visit our website can find us.

Tags

Links

E-Articles - The FDA May Expand Warning Labels for Antidepressants

Related Articles: